Performance Evaluation of a Point of Care SelexOnTM B-Type Natriuretic Peptide Immunoassay
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: This study was conducted to evaluate the analytical performance of the SelexOnTM B-type natriuretic peptide (BNP) assay (Osang Healthcare Inc., Korea), a new rapid lateral flow immunoassay for point of care (POC) testing using whole blood. Methods: The imprecision, linearity, and method comparison of SelexOnTM BNP assay were evaluated. Two commercial BNP assays, the ADVIA Centaur® BNP (Siemens Health Care diagnostics Inc., USA) and the Triage® BNP assays (Alere, USA), were included for method comparison using 100 whole blood samples from patients. The reference interval was verified using 120 residual samples from health examination participants. Results: The SelexOn BNP had total CVs of 20.3%, 13.3%, and 10.3% in BNP concentrations of 89.44 pg/mL, 480.71 pg/mL, and 1,201.84 pg/mL of control materials, respectively. Linearity was observed from 56 pg/mL to 1544 pg/mL. The SelexOn BNP (y) regression equation was y=0.9706x-21.68 with Centaur BNP (x) (r=0.930) and y=0.7600x+0.0506 with Triage BNP (x) (r=0.845), respectively. The predicted mean difference (%) of the SelexOn BNP at the clinical decision levels (100 pg/mL) was up to 25% lower than the two comparative methods. The SelexOn BNP levels were below 50 pg/mL in 114 (95%) of the 120 samples. Conclusions: The SelexOn BNP using EDTA was developed as a POC test for differential diagnosis or treatment monitoring for acute heart failure. However, clinical decision values must be improved to be compatible with other BNP methods.
Abstract
Background: This study was conducted to evaluate the analytical performance of the SelexOnTM B-type natriuretic peptide (BNP) assay (Osang Healthcare Inc., Korea), a new rapid lateral flow immunoassay for point of care (POC) testing using whole blood. Methods: The imprecision, linearity, and method comparison of SelexOnTM BNP assay were evaluated. Two commercial BNP assays, the ADVIA Centaur® BNP (Siemens Health Care diagnostics Inc., USA) and the Triage® BNP assays (Alere, USA), were included for method comparison using 100 whole blood samples from patients. The reference interval was verified using 120 residual samples from health examination participants. Results: The SelexOn BNP had total CVs of 20.3%, 13.3%, and 10.3% in BNP concentrations of 89.44 pg/mL, 480.71 pg/mL, and 1,201.84 pg/mL of control materials, respectively. Linearity was observed from 56 pg/mL to 1544 pg/mL. The SelexOn BNP (y) regression equation was y=0.9706x-21.68 with Centaur BNP (x) (r=0.930) and y=0.7600x+0.0506 with Triage BNP (x) (r=0.845), respectively. The predicted mean difference (%) of the SelexOn BNP at the clinical decision levels (100 pg/mL) was up to 25% lower than the two comparative methods. The SelexOn BNP levels were below 50 pg/mL in 114 (95%) of the 120 samples. Conclusions: The SelexOn BNP using EDTA was developed as a POC test for differential diagnosis or treatment monitoring for acute heart failure. However, clinical decision values must be improved to be compatible with other BNP methods.
참고문헌 (18)
- Fu S, "Brain natriuretic peptide and its biochemical, analytical, and clinical issues in heart failure : A narrative review", Front Physiol, 9, pp.692~ (2018)
- Semenov AG, "Searching for a BNP standard : Glycosylated proBNP as a common calibrator enables improved comparability of commercial BNP immunoassays", Clin Biochem, 50, pp.181~185 (2017)
- Dickstein K, "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC(HFA)and endorsed by the European Society of Intensive Care Medicine(ESICM)", Eur J Heart Fail, 10, pp.933~989 (2008)
- Clinical and Laboratory Standards Institute, "User verification of precision and estimation of bias; Approved guideline" (2014), Clinical and Laboratory Standards Institute
- Apple FS, "Quality specifications for B-type natriuretic peptide assays", Clin Chem, 51, pp.486~493 (2005)
- Clinical and Laboratory Standards Institute, "Evaluation of the linearity of quantitative measurement procedures: A statistical approach; Approved guideline" (2003), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Measurement procedure comparison and bias estimation using patient samples; Approved guideline" (2013), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline" (2010), Clinical and Laboratory Standards Institute
- Plebani M, "Natriuretic peptides and evidence-based quality specifications", Clin Chem Lab Med, 44, pp.355~357 (2006)
- Wu AH, "Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure : a multisite study", Clin Chem, 50, pp.867~873 (2004)
- Clerico A, "Clinical relevance of biological variation : the lesson of brain natriuretic peptide(BNP)and NT-proBNP assay", Clin Chem Lab Med, 44, pp.366~378 (2006)
- Bruins S, "High intraindividual variation of B-type natriuretic peptide(BNP)and amino-terminal proBNP in patients with stable chronic heart failure", Clin Chem, 50, pp.2052~2058 (2004)
- Ponikowski P, "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)
- Prontera C, "Proficiency testing project for brain natriuretic peptide(BNP)and the N-terminal part of the propeptide of BNP(NT-proBNP)immunoassays : The CardioOrmocheck study", Clin Chem Lab Med, 47, pp.762~768 (2009)
- 강소영, "Access 2 및 AxSYM에 의한 BNP 검사와 Triage BNP 현장검사법과의 비교", Annals of Laboratory Medicine, 25(5), pp.300~305 (2005), 대한진단검사의학회
- Clerico A, "New issues on measurement of B-type natriuretic peptides", Clin Chem Lab Med, 56, pp.32~39 (2017)
- Alehagen U, "Reference intervals and decision limits for B-type natriuretic peptide(BNP)and its precursor(Nt-proBNP)in the elderly", Clin Chim Acta, 382, pp.8~14 (2007)
- Keyzer JM, "Age-and gender-specific brain natriuretic peptide(BNP)reference ranges in primary care", Clin Chem Lab Med, 52, pp.1341~1346 (2014)